- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Should You Be Bullish on Arcellx (ACLX)? | 1 | Insider Monkey | ||
| 25.03. | Arcellx director sells over $35 million in company stock | 1 | Investing.com | ||
| 19.03. | Arcellx CFO sells over $470k in company stock | 1 | Investing.com | ||
| 18.03. | Arcellx director Ware sells over $630k in company stock | 1 | Investing.com | ||
| 18.03. | Needham raises Arcellx stock target to $81, maintains buy rating | - | Investing.com | ||
| 14.03. | Arcellx, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.03. | Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley | 14 | Benzinga.com | ||
| 07.03. | Morgan Stanley bullish on Arcellx shares after myeloma data 'promising' | 5 | Investing.com | ||
| 05.03. | Arcellx shares target raised by Truist on CAR-T potential | 3 | Investing.com | ||
| 29.02. | Arcellx Analysts Boost Their Forecasts After Q4 Results | 1 | Benzinga.com | ||
| 28.02. | Arcellx, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.02. | Arcellx, Inc.: Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights | 650 | PR Newswire | -- Expanded strategic partnership with Kite --
-- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractory... ► Artikel lesen | |
| 31.01. | Arcellx, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.01. | Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024 | 2 | Benzinga.com | ||
| 04.01. | Needham Maintains Buy Rating for Arcellx: Here's What You Need To Know | 1 | Benzinga.com | ||
| 02.01. | Arcellx, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 28.12.23 | Arcellx, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.12.23 | Arcellx rises as brokerage Leerink lifts PT | 3 | Reuters | ||
| 11.12.23 | Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say | 3 | Benzinga.com | ||
| 11.12.23 | Where Arcellx Stands With Analysts | 2 | Benzinga.com |
Seite:
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,580 | -3,07 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,850 | 0,00 % | Aufholjagd BioTech 2024 - jetzt positionieren! Bayer, BioNTech, Defence Therapeutics, Evotec, BioNxt und Vidac Pharma im Fokus | BioTech-Investoren haben im Jahr 2024 bislang noch keine große Party feiern können. Das blieb eher den Spekulanten in den Sektoren Künstliche Intelligenz und Rüstung vorbehalten. Doch nun neigen sich... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,780 | -7,04 % | Collaboration advancing new sourdough strain: Ginkgo Bioworks working with Italian baking ingredients company | ||
| BEAM THERAPEUTICS | 21,600 | -5,01 % | Expert Ratings For Beam Therapeutics | ||
| ONCOLYTICS BIOTECH | 1,030 | +4,04 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting | SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology,... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,840 | -1,26 % | Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX | ||
| ARCTURUS THERAPEUTICS | 26,170 | -3,00 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,785 | -9,30 % | Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 | ||
| SIGA TECHNOLOGIES | 8,640 | -0,23 % | SIGA Technologies - Positive signals abound | SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 14,730 | +0,14 % | Merrimack Pharmaceuticals, Inc. Reports Full Year 2023 Financial Results | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,630 | -5,10 % | How Vir found the one: CEO Marianne De Backer | ||
| VERVE THERAPEUTICS | 6,220 | -5,47 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 8,090 | -2,06 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy (Epinephrine Nasal Spray) | Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC) conditions, and updated testing that detected... ► Artikel lesen | |
| BIO-PATH | 2,635 | +5,40 % | Bio-Path files to sell 484K shares of common stock for holders | ||
| BIOMEA FUSION | 10,470 | -2,79 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
ARCELLX INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -2,73 % bei einem Aktienkurs von 51,38 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
